From SAR to comparative QSAR: role of hydrophobicity in the design of 4-hydroxy-5,6-dihydropyran-2-ones HIV-1 protease inhibitors.

Role of hydrophobicity in the design of 4-hydroxy-5,6-dihydropyran-2-ones-a new class of emerging HIV-1 protease inhibitors (HIV-PI) was investigated by using comparative QSAR. These studies show that most of the data points in the individual dataset studied fall either on positive or negative side of the optimum value of ClogP. This is why, we observe either a positive or negative ClogP term in the QSAR. To observe the optimum value of ClogP for these inhibitors, a sufficient spread in the data is required. It is hoped that the results of this study would help in optimizing substituents for better binding at enzyme pockets and guide in the design of more effective HIV-PI of this class.

[1]  A. Berger,et al.  On the size of the active site in proteases. I. Papain. , 1967, Biochemical and biophysical research communications.

[2]  R. Babine,et al.  MOLECULAR RECOGNITION OF PROTEIN-LIGAND COMPLEXES : APPLICATIONS TO DRUG DESIGN , 1997 .

[3]  Tomi K. Sawyer,et al.  A synthetic HIV-1 protease inhibitor with antiviral activity arrests HIV-like particle maturation. , 1990, Disease markers.

[4]  L J Davis,et al.  Active human immunodeficiency virus protease is required for viral infectivity. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[5]  A. Leo.  CALCULATING LOG POCT FROM STRUCTURES , 1993 .

[6]  T. Copeland,et al.  Gag precursors of HIV and SIV are cleaved into six proteins found in the mature virions. , 1990, Journal of medical primatology.

[7]  Corwin Hansch,et al.  On the Role of Polarizability in Chemical-Biological Interactions , 2003, J. Chem. Inf. Comput. Sci..

[8]  C. Hansch,et al.  Comparative Quantitative Structure−Activity Relationship Studies on Anti-HIV Drugs , 1999 .

[9]  J. Sodroski,et al.  Role of capsid precursor processing and myristoylation in morphogenesis and infectivity of human immunodeficiency virus type 1. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[10]  B. Haynes,et al.  Frequent detection and isolation of cytopathic retroviruses (HTLV-III) from patients with AIDS and at risk for AIDS. , 1984, Science.

[11]  S. Mehandru,et al.  Tipranavir: a novel non-peptidic protease inhibitor for the treatment of HIV infection , 2003, Expert opinion on investigational drugs.

[12]  Quantitative structure-activity relationships of some HIV-protease inhibitors. , 1999, Journal of enzyme inhibition.

[13]  D. E. Patterson,et al.  Crossvalidation, Bootstrapping, and Partial Least Squares Compared with Multiple Regression in Conventional QSAR Studies , 1988 .

[14]  B. Dunn.  Structure and Function of the Aspartic Proteinases , 1991 .

[15]  A quantitative structure-activity relationship study on some sulfolanes and arylthiomethanes acting as HIV-1 protease inhibitors. , 1998, Bioorganic & medicinal chemistry.

[16]  Quantitative structure-activity relationship studies on cyclic urea-based HIV protease inhibitors. , 1998, Journal of enzyme inhibition.

[17]  Erik De Clercq,et al.  New anti‐HIV agents and targets , 2002, Medicinal research reviews.

[18]  J. Chermann,et al.  Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). , 1983, Science.

[19]  R. Gulick.  New antiretroviral drugs. , 2003, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[20]  C. Hansch,et al.  Molecular graphics and QSAR in the study of enzyme-ligand interactions. On the definition of bioreceptors , 1986 .

[21]  George W. A. Milne,et al.  Discovery of novel, non-peptide HIV-1 protease inhibitors by pharmacophore searching. , 1996, Journal of medicinal chemistry.

[22]  C. Humblet,et al.  4-hydroxy-5,6-dihydropyrones. 2. Potent non-peptide inhibitors of HIV protease. , 1997, Journal of medicinal chemistry.

[23]  Rajni Garg,et al.  A mechanistic study of 3-aminoindazole cyclic urea HIV-1 protease inhibitors using comparative QSAR. , 2004, Bioorganic & medicinal chemistry.

[24]  J. Strohbach,et al.  Non-peptidic HIV protease inhibitors. , 2004, Current topics in medicinal chemistry.

[25]  C. Hansch,et al.  Comparative QSAR and the radical toxicity of various functional groups. , 2002, Chemical reviews.

[26]  R. McLeod,et al.  Immunogenetics in pathogenesis of and protection against toxoplasmosis. , 1996, Current topics in microbiology and immunology.

[27]  Rajni Garg,et al.  HIV-1 protease inhibitors: a comparative QSAR analysis. , 2003, Current medicinal chemistry.

[28]  P. Darke,et al.  Synthesis and antiviral activity of a series of HIV-1 protease inhibitors with functionality tethered to the P1 or P1' phenyl substituents: X-ray crystal structure assisted design. , 1992, Journal of Medicinal Chemistry.

[29]  V. Turk,et al.  Human immunodeficiency virus has an aspartic-type protease that can be inhibited by pepstatin A. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[30]  B. Ho,et al.  Role of human immunodeficiency virus type 1-specific protease in core protein maturation and viral infectivity , 1989, Journal of virology.

[31]  A quantitative structure-activity relationship study on some HIV-1 protease inhibitors using molecular connectivity index. , 2001, Bioorganic & medicinal chemistry.